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V aricella zoster virus (VZV) infection is a common pediatric illness with a broad spectrum of severity. Although the vast majority of affected children experience a benign course, one of every 1000 cases of chickenpox is estimated to require hospitalization (1) . There is only one study examining children hospitalized with VZV infections since acyclovir became available (2) , and it is restricted to previously healthy children admitted because of a complication of varicella. Recent information about other pediatric patient populations and reasons for admission related to VZV infections is lacking. Varicella vaccine was recently released in United States, and licensure is anticipated soon in Canada. We designed a retrospective study to describe the clinical course and outcome of patients admitted to our institution to allow monitoring of the impact of vaccine introduction.
METHODS

Patient profile:
The Alberta Children's Hospital, Calgary, Alberta (ACH) is a 144-bed university-affiliated primary, secondary and tertiary care centre serving a population of 1.2 million in southern Alberta, southwestern British Columbia and southeastern Saskatchewan. On average, there are about 6500 admissions per annum to the institution. The health records of all patients 18 years of age or younger who presented with varicella infection between January 1, 1983 and December 31, 1992 were reviewed. Included in the study were all patients with a discharge diagnosis of varicella, zoster, and/or Reye's syndrome. Cases were excluded if the child developed varicella after admission and did not require any supportive or specific therapy. In most of these cases, the child had been admitted for an elective surgical procedure and was discharged immediately upon diagnosis of VZV infection. A standardized data collection form was used to extract the following information from health records: age; sex; primary or reactivated VZV infection; presence of underlying immune defect (including any malignancy, organ transplantation or condition being treated with immunosuppressive corticosteroid doses) or nonimmunocompromising condition (any condition leading to multiple investigations, hospitalizations and/or physician visits, including those on replacement doses of corticosteroids, ie, less than 15 mg/m 2 /day methylprednisolone); investigations in- 
RESULTS
Two hundred and one children were identified, of whom 36 (17.9%) were excluded due to hospitalization for other reasons, leaving 165 (82.1%) evaluable. There were 2.6 varicella infections for every 1000 admissions to ACH over the study period (range 1.2 to 4.5); however, the number of cases per 1000 admissions increased significantly during the study (P<0.01).
Demographic characteristics and clinical presentation are shown in Table 1 . The proportion of immunocompromised patients increased from 28.1% in the first five years to 40.0% in the last five years (P=0.13). All patients admitted with zoster (16) were either immunocompromised (13 of 60, 21.7%) or had a nonimmunocompromising condition (three of 35, 8.6%; difference P=0.15).
Three major reasons for hospitalization were identified ( Figure 1 ). Treatment of complication of VZV infection was the most common (92, 55.8%) followed by antiviral therapy to prevent dissemination (62, 37.6%) and supportive care only (11, 6 .7%), but differed significantly by underlying patient health status ( Figure 1 ). The relative frequency of admission for each indication was stable over the study period (P=0.6).
One hundred and seven complications occurred in 92 pa- tients (Table 2) Frequency of complication on admission decreased with increasing age, occurring in 53 of 80 (66.3%) children under five years of age and 36 of 64 (56.3%) of five-to 10-year-olds compared with three of 21 (14.3%) of those over 10 years. However, children over ten years of age were more likely to be immunocompromised (15 of 21, 71.4%) compared with those 10 years of age or younger (45 of 144, 31.3%; P<0.0001). Patient age also appeared to be related to complication site ( Figure 3) .
Use of antiviral therapy in absence of viral dissemination occurred only in children with underlying medical conditions (Figure 1 ). Of the nine children (25.7%) with a nonimmunocompromising condition who received antiviral medication, four had endocrinopathies and received replacement doses of corticosteroids, two had congenital heart disease, two had chronic skin disease (eczema, lamellar icthyosis) and one had portal hypertension (with noncorneal V-1 zoster).
Among immunocompromised patients who received antiviral therapy for any reason, the route and duration of treatment varied. Forty-eight (80.0%) were given antiviral therapy (acyclovir in all but one case who received vidarabine) intravenously only for a mean duration of 5.4 days. Those with complications (five of 48) received a longer duration compared with those without complications (7.6 versus 5.2 days). Acyclovir, intravenous adminstration followed by oral, was given in eight uncomplicated cases (13.3%) for a mean of eight days (four days each intravenous and oral). One patient with zoster received five days of oral acyclovir alone. Two patients with solid tumours and zoster and one with nephrotic syndrome and varicella/peritonitis did not receive antiviral therapy.
Morbidity and mortality were low both overall and by subgroups (Table 3) .
DISCUSSION
This hospital-based study describes the epidemiology of immunocompromised and immunocompetent children admitted with VZV infection before the vaccine era. Study populations reported in two other publications since 1980 (2,3) differ from ours, with one being conducted before the licensure of acyclovir (3) and the other including only immunologically normal children (2) . Immunocompromised patients accounted for less than 20% of all pediatric hospitalizations in the 1981 study (3), contrasting with 36% in our population. A study based on data from an American health maintenance organization noted 21 pediatric hospital admissions but did not include information about underlying conditions (4) . The majority of the increase in the annualized VZV admissions over the 10-year period was accounted for by immunocompromised children, suggesting that this population has either increased relative to nonimmunocompromised patients and/or has become more likely to be admitted for acyclovir therapy.
Although occasionally noted as a subgroup of immunologically normal children (2, 3) , those with a nonimmunocompromising condition have not previously been examined as a specific group of interest. In our population, they made up one-fifth of all pediatric VZV admissions. This group was intermediate between healthy and immunocompromised children in their relative frequency of admissions for treatment of complications and use of acyclovir to prevent dissemination.
Treatment of complications was the most frequent reason for children to be admitted to hospital with VZV infections. As in previous studies, skin and soft tissue infections predominated (1-3), followed by neurological complications. Reye's syndrome was not identified in any of our patients, consistent with recent studies showing that the latter complication was decreasing (2) or absent (4) by 1990. As expected, the severity appeared to be greatest among the immunocompromised children.
Half of all the complications necessitating admission in this study were the result of a bacterial infection. S pyogenes and S aureus were equally likely to cause invasive infections (3, 5) . Invasive S pyogenes infections have been of particular concern recently (6,7), with risk of varicella estimated to be almost 40 times that of the general population (8) . Notably, skin and soft tissue superinfections did not occur in the immunocompromised group despite that this group was not given antibiotics empirically. This may be due in part to age differences (immunocompromised patients were older than immunocompetent children and therefore may be less likely to have skin and soft tissue infection) and the rapid institution of acyclovir for VZV infection in most of these patients.
Complications as a reason for admission in children increased with decreasing age and varied in type and location across different age categories. Because the majority of varicella infections occur in children under 10 years (9), the absolute number of complications would also be expected to be highest in this age group. A bias towards admission of younger VZV-infected patients to ACH compared with two other institutions in the city (with a total of 40 pediatric beds during the study period versus 144 beds at ACH) could also account for this, although there is no evidence to support this. One previous population-based study found that proportionately more adolescents and adults get complications with varicella than children; adult complications consist mostly of neurological abnormalities, whereas skin and soft tissue infections were most common in the youngest age group (less than five years) (1). While authors have speculated that younger children may be more prone to secondary bacterial infection (3), a recent community-based study found that skin and soft tissue infections might occur as frequently in older pediatric patients (4) . A greater likelihood of hospitalization for bacterial superinfection in the preschool age group may explain the apparent higher frequency of such complications in hospital-based studies such as this one.
Antiviral therapy for uncomplicated VZV infection was also a common reason for admission, not only among the immunocompromised, but also in some children with nonimmunocompromising conditions. Use of acyclovir for those with either cardiac disease or on physiological replacement doses of corticosteroids suggested an underlying concern about more severe manifestations in these patient populations. Exacerbation of conditions such as insulin-dependent diabetes mellitus (3) and cystic fibrosis (10,11) due to varicella have been noted previously. These findings suggest that there may be real or perceived reasons other than immunocompromising conditions that place children at increased risk of severe or complicated VZV infection. Whether this is true and these children warrant treatment with acyclovir remains to be demonstrated.
Acyclovir was predominately used for prevention of dissemination in immunocompromised patients. Although the mean duration of treatment was shorter than recommended by some authorities (12) , in several cases where intravenous and oral acyclovir were used sequentially, no relapses occurred. Others have reported treatment with oral acyclovir in a similar population (13) , but this is not considered standard therapy. Patients with complications did receive a longer course of antiviral treatment compared with those without complications.
Previous reviews of varicella in children have found a low mortality rate with figures ranging from a population-based estimate of two deaths per 100,000 cases of varicella (14) to 1% in hospitalized cases (2) . Although our study differs from the latter (2) because of the inclusion of immunocompromised children, the mortality rate (0.6%) was similar. Given the improved outcome with antiviral treatment (15) , this figure likely reflects the use of antiviral medications in the majority of patients in this group. In this study, we demonstrate that VZV infection remains a significant cause of hospitalization and morbidity in our population in the prevaccine era. Previous studies have shown the cost and benefits of immunizing healthy children against VZV (16, 17) . Vaccine efficacy is estimated to be 90% (18) or more (19) in immunocompetent hosts and similar in leukemic children who seroconvert (20) . Thus, the vaccine would be expected to prevent the majority of wild type varicella cases, particularly if most children are immunized before becoming immunocompromised. Even with a higher vaccine failure rate in immunocompromised childrenvaccine failure rates range from 10% to 90% -an economic evaluation of varicella vaccine before pediatric liver and kidney transplantation was able to demonstrate a net savings (21) . Based on the results of this study, we would expect significant savings would result from fewer hospitalizations and therefore a reduction in acyclovir use in immunocompromised children.
While zoster still occurs postimmunization, it appears to happen less frequently than after wild type infection (22) . In the long term, a mathematical model of VZV vaccine effectiveness predicts that after 10 years with 70% coverage, the number of VZV cases would drop to less than 30% of prevaccine numbers of cases, and would virtually cease altogether with 97% coverage (23) .
CONCLUSIONS
Before the introduction of the varicella vaccine, secondary complications were the most common reason for a child to be admitted to this hospital with a VZV infection. Complications varied with underlying condition and age. Subgroup analyses showed that the most common reason for admission included bacterial superinfections in nonimmunocompromised children and early antiviral therapy in immunocompromised children. With certain nonimmunocompromising conditions, even though they are not noted in current recommendations (12, 24) , there was a perception of increased risk resulting in a decision to treat with acyclovir in the absence of known complications. A universal varicella vaccination program would be expected to lead to reduced circulation of wild type virus and infections, resulting in fewer VZV-related admissions in both immunocompromised and immunocompetent children, and can be monitored after introduction of VZV vaccine.
